Navigation Links
Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel
Date:6/1/2009

Data indicate target-dependent activity in breast cancer patients with high expression of EpCAM

ORLANDO, Fla., June 1 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, presented data from a clinical trial investigating its anti-EpCAM human antibody adecatumumab (MT201) in combination with the chemotherapeutic docetaxel in patients with metastatic breast cancer (MBC) at the annual meeting of the American Society of Clinical Oncology (ASCO) held in Orlando, Florida, USA(1).

The phase 1b clinical trial presented at ASCO investigates the safety and tolerability of increasing doses of adecatumumab given every 3 weeks in combination with standard chemotherapy docetaxel (Taxotere(R)) in relapsed MBC patients who had a median of three prior chemotherapy regimens (n=22 assessable for safety and n=19 evaluable for efficacy). Adecatumumab is an antibody that targets EpCAM, a tumor antigen known to be associated with poor prognosis for breast cancer patients. Combining adecatumumab with docetaxel was feasible with clinically manageable diarrhea being the main toxicity at higher doses. Other frequently observed adverse events included nausea, vomiting, stomatitis, constipation, fatigue, fever and chills. Laboratory abnormalities included reduction in various blood cells such as lymphocytes and neutrophils comparable to what is typically observed with docetaxel monotherapy.

The overall response rate according to RECIST [version 1.0] was 38% in patients with high expression of EpCAM (n=8), the target of adecatumumab, compared to 9% in patients with low EpCAM expression (n=11). Patients treated with higher doses of adecatumumab also appeared to have a longer time to progression when compar
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
2. Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009
3. Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110
4. Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009
5. Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics
6. Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research
7. Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008
8. Micromet to Present at the Cowen Health Care Conference on March 17, 2009
9. Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
10. Micromet to Present at the BIO CEO and Investor Conference on February 10, 2009
11. Micromet Enters Into Agreement for Solid Tumor BiTE Antibody with Bayer Schering Pharma AG
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... VIEJO, Calif. , Dec. 22, 2014  ( ... that CoPatient, an online medical bill review and advocacy ... offering in the FREE WellCard Savings discount health services ... medical bill that was more than they expected to ... members reduce health care costs, WellCard Savings is pleased ...
(Date:12/22/2014)... December 22, 2014 Fertility Associates of ... Egg Bank USA , a network of more than ... this partnership, patients have fast access to a national ... fertilization, IVF . Fertility Associates of Memphis is the ... fertility treatment option. , Dr. William Kutteh , ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), ... promotion of Nick Maroulis, Pharm.D. to the newly created ... , In this position, Dr. Maroulis will continue to ... directors of our multi-site pharmacies as the company expands. ... during that time he has served in many different ...
(Date:12/19/2014)... , Dec. 19, 2014 Bina Technologies, Inc. ... announced today that they have been acquired by Roche ... is a privately held company that provides a big ... generation sequencing (NGS) data for the academic and translational ... Sequencing Unit, and will continue to focus on development ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... June 24 ,WuXi PharmaTech (NYSE: WX ) ... announced,that the two companies have entered into a ... which will provide world-class preclinical,contract research services in ... located in a 323,450 square-foot, purpose-built facility in,Suzhou, ...
... The Board of,Directors of Schering-Plough Corporation (NYSE: ... per common share. Payment will be made on,Aug. 26, ... business on Aug.,1, 2008. As of March 31, 2008, ... Directors today also declared a quarterly dividend of,$3.75 per ...
... Sun Pharmaceutical,Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: ... Levitt, Chairman of the Board,of Directors of Taro Pharmaceutical ... Levitt,s letter of June 19, 2008 to Taro,s,shareholders, his ... the Initiating,Motion filed by Taro in the Tel-Aviv District ...
Cached Biology Technology:Covance and WuXi PharmaTech to Form a Joint Venture to Provide World-Class Preclinical Services in China 2Covance and WuXi PharmaTech to Form a Joint Venture to Provide World-Class Preclinical Services in China 3Covance and WuXi PharmaTech to Form a Joint Venture to Provide World-Class Preclinical Services in China 4Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro's Irish Subsidiary 2Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro's Irish Subsidiary 3Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro's Irish Subsidiary 4Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro's Irish Subsidiary 5Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro's Irish Subsidiary 6Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro's Irish Subsidiary 7
(Date:12/10/2014)... Dec. 08, 2014 Research and Markets ... of the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration ... as rural banking and upgradation of the driver,s ... in the market. Besides the aforementioned projects, biometrics ...
(Date:12/5/2014)... -- Tute Genomics, a leader in cloud-based solutions for genome ... led by UK-based Eurovestech. Peak Ventures and a number ... "We are at a pivotal time in ... seeks new approaches for the diagnosis, treatment and prevention ... and CEO of Tute Genomics. "One of the main ...
(Date:12/3/2014)... 2014 As part of our commitment to ... pleased to announce the release of a new reader ... the workforce data that they need. The ... by existing readers. Many such devices have serious shortcomings ... technology. Older models force users to navigate numerous complicated ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Inception Technologies to Release New Biometric Reader 2
... every day, especially wine, may be associated with an ... Dutch researchers who reported the findings of their study ... on Cardiovascular Disease Epidemiology and Prevention. , The researchers ... less than one glass per day) was associated with ...
... the University of Pennsylvania School of Medicine have discovered ... replication within cells -- use proteins that act as ... structure. If microtubules are not formed properly such basic ... which may have implications in such disease processes as ...
... on Mars do not drill deep enough to find the ... surface of Mars, according to research led by UCL (University ... that life once existed on Mars, cellular life could not ... the surface of Mars than a few metres deep ?beyond ...
Cached Biology News:Light wine intake is associated with longer life expectancy in men 2Light wine intake is associated with longer life expectancy in men 3Light wine intake is associated with longer life expectancy in men 4Molecular motors and brakes work together in cells 2Dig deeper to find Martian life 2Dig deeper to find Martian life 3
... Reagent B - Permeabilisation medium LEUCOPERM ... suspension with Reagent A and then permeabilising ... gives antibodies access to intracellular structures and ... cells intact. Specific formulations reduce background staining ...
...
Collected from calves that are 10 days old or less. Sterile, cell culture tested, US Origin...
Dako Target Retrieval Solution, Citrate pH 6 (x 10) For more information, please visit Dako' web-site. EU regulatory status: CE US regulatory status: IVD...
Biology Products: